<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:08:55Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/16559" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/16559</identifier><datestamp>2026-09-24T01:12:40Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Bramson, Jonathan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">VanSeggelen, Heather</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Health Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-12-16T15:27:27Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-12-16T15:27:27Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2015-06</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/16559</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/11506</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">INTRODUCTION: Immunotherapy continues to garner strong support for use in the treatment of cancer. Adoptive transfer therapies offer a promising approach to combating metastatic disease. In addition, viruses can also be exploited to drive antitumor immunity and tumor destruction. While the use of chimeric antigen receptor (CAR)-engineered T cells has shown dramatic clinical benefit for use in blood-based cancers, solid tumors remain a significant hurdle.&#xd;
METHODS: We have investigated the use of multi-faceted immunotherapies combining CAR-T cells with oncolytic virotherapy. We have also evaluated how these therapies interact with pre-conditioning lymphodepletion regimes.&#xd;
RESULTS: In chapter 3, we investigated the differences between three similar chimeric receptors targeting NKG2DL. Upon adoptive transfer, we observed dramatic T cell-induced toxicity. In addition, there were stark differences in the severity of toxicity induced between different receptors or across different mouse strains, or if combined with pre-conditioning chemotherapy.&#xd;
In chapter 4, we tested the ability of oncolytic vaccines to boost engineered T cells through their natural antigen receptor. While CAR-T cells could be boosted via oncolytic vaccines, prolonged T cell engraftment and successful oncolytic vaccine boost required pre-conditioning chemotherapy.&#xd;
Further analysis revealed a lack of antitumor function of the CAR-T cells in vivo. iii&#xd;
In chapter 5, we evaluated loading CAR-T cells with oncolytic viruses (OVs). Loading of CAR-T cells with OV did not impair CAR expression or functionality of the T cells. In addition, CAR target recognition did not impact the ability of OV-loaded cells to deposit OVs onto tumor targets. CAR-T cells loaded with OV also displayed enhanced antitumor functions as compared to either treatment alone.&#xd;
CONCLUSIONS: The research described in this thesis reveals important information into the interactions between CAR-T cells and OVs, and how pre- conditioning regimes may influence responses from either or both therapies. Overall, our research offers novel insight into future CAR-T cell therapeutic developments.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">immunology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">oncology</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Combining CAR-T cells and Oncolytic Viruses for Cancer Immunotherapy</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>